Issledovanie III fazy: znachitel'noe uvelichenie prodolzhitel'nosti zhizni u patsientov s naibolee rasprostranennym tipom nemelkokletochnogo raka legkogo, poluchavshikh prodolzhennuyu podderzhivayushchuyu terapiyu na osnove preparata Alimta

Cite item

Full Text

Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
Ciuleanu T et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374 (9699): 1432-40.
Paz-Ares LG et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29: abstract CRA 7510.

Supplementary Files

Action

1. JATS XML